Skip to main content
. 2022 Feb 16;6(4):1255–1263. doi: 10.1182/bloodadvances.2021005385

Figure 2.

Figure 2.

Cohort survival. PFS (A) and OS (B) for all patients treated with CD30.CAR-T cell therapy.